Patient-derived organoids model treatment response of metastatic gastrointestinal cancers
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
Cancer organoids to model therapy response: Cancer organoids are miniature, three-dimensional cell culture models that can be made from primary patient tumors and studied in the laboratory. Vlachogiannis et al. asked whether such “tumor-in-a-dish” approaches can be used to predict drug responses in the clinic. They generated a live organoid biobank from patients with metastatic gastrointestinal cancer who had previously been enrolled in phase I or II clinical trials. This allowed the authors to compare organoid drug responses with how the patient actually responded in the clinic. Encouragingly, the organoids had similar molecular profiles to those of the patient tumor, reinforcing their value as a platform for drug screening and development. Science , this issue p. 920
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“a living biobank of cancer PDOs from patients with metastatic and pre-treated colorectal and gastroesophageal cancer shows strong morphological, genotypic and spatiotemporal similarities between the primary tumour and the PDOs123.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“revealing strong correlations between in vitro and in vivo drug responses against cancer in the gastrointestinal tract123, bladder124, ovary125, rectum126 and pancreas127,128.”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“PDOs reliably predicted treatment responses in patients, with 100% sensitivity, 93% specificity, 88% positive predictive value and 100% negative predictive value, including response to taxanes and anti-EGFR antibodies”
From Human disease models in drug development (2023) · cites this paper as [123]
In the citing paper
“These models have been particularly important in the search for anticancer compounds as they can predict patient outcomes in phase 1/2 clinical trials for gastrointestinal cancer [55].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [55]
In the citing paper
“these primary tumor clusters significantly triggered the angiogenic sprouting of HUVECs.”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [113]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298
Mapping and quantifying mammalian transcriptomes by RNA-Seq
Mortazavi, A., Williams, B. A., McCue, K., Schaeffer, L., & Wold, B. (2008) · Nature Methods · doi:10.1038/nmeth.1226 · Cited by 13,696
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal Research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · PLoS Biology · doi:10.1371/journal.pbio.1000412 · Cited by 7,300
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Zehir, A., Benayed, R., Shah, R. H., Syed, A., Middha, S., Kim, H. R., Srinivasan, P., Gao, J., Chakravarty, D., Devlin, S. M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4333 · Cited by 3,380
Prospective Derivation of a Living Organoid Biobank of Colorectal Cancer Patients
van de Wetering, M., Francies, H. E., Francis, J. M., Bounova, G., Iorio, F., Pronk, A., van Houdt, W., van Gorp, J., Taylor-Weiner, A., Kester, L., et al. (2015) · Cell · doi:10.1016/j.cell.2015.03.053 · Cited by 2,408
Cited by
Items 501–600 of 1,001
SMAD7 expression in CAR-T cells improves persistence and safety for solid tumors
Liang, S., Zheng, R., Zuo, B., Li, J., Wang, Y., Han, Y., Dong, H., Zhao, X., Zhang, Y., Wang, P., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01120-y · Cited by 47
Advances in human organs-on-chips and applications for drug screening and personalized medicine
Zhou, C., Li, Z., Lu, K., Liu, Y., Xuan, L., Mao, H., & Wang, X. (2024) · Fundamental Research · doi:10.1016/j.fmre.2023.12.019 · Cited by 44
“Previously, some patient-derived organoids (PDO) from colorectal and gastroesophageal cancer patients showed high similarity to the patients’ original tumors in phenotypic and genotypic profiling [125] .”
Advancing cancer research through organoid technology
Zeng, G., Yu, Y., Wang, M., Liu, J., He, G., Yu, S., Yan, H., Yang, L., Li, H., & Peng, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-024-05824-1 · Cited by 51
“…and actual patient responses to anti-cancer drugs in clinical trials, it has been discovered that PDTO subjected to anticancer treatments not only undergo further validation in PDTO-based xenograft models but also effectively recapitulate patient responses to treatment in clinical trials [95, 96].”
BackgroundMonitoring Immune Responses in Neuroblastoma Patients during Therapy
Szanto, C. L., Cornel, A. M., Vijver, S. V., & Nierkens, S. (2020) · Cancers · doi:10.3390/cancers12020519 · Cited by 44
“This strategy has previously shown to be effective in metastatic gastrointestinal cancers, in which patient derived organoids were instrumental in the prediction of tumor specific responses, stimulating personalized treatment strategies [121].”
BackgroundFlorent, R., Weiswald, L., Lambert, B., Brotin, É., Abeilard, E., Louis, M.-H., Babin, G., Poulain, L., & N’Diaye, M. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-2588-8 · Cited by 45
Dhumal, D. M., Lan, W., Ding, L., Jiang, Y., Lyu, Z., Laurini, E., Marson, D., Tintaru, A., Dusetti, N., Giorgio, S., et al. (2020) · Nano Research · doi:10.1007/s12274-020-3216-8 · Cited by 46
Parihar, A., Pandita, V., & Khan, R. (2022) · Biotechnology and Bioengineering · doi:10.1002/bit.28166 · Cited by 41
Martini, G., Belli, V., Napolitano, S., Ciaramella, V., Ciardiello, D., Belli, A., Izzo, F., Avallone, A., Selvaggi, F., Tasselli, F. M., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101198 · Cited by 40
Experimental Murine Models for Colorectal Cancer Research
Neto, Í., Rocha, J. P., Gaspar, M. M., & Reis, C. P. (2023) · Cancers · doi:10.3390/cancers15092570 · Cited by 54
Patient‐Derived Microphysiological Systems for Precision Medicine
Ko, J., Song, J., Choi, N., & Kim, H. N. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303161 · Cited by 46
Microbiome and pancreatic cancer: time to think about chemotherapy
de Castilhos, J., Tillmanns, K., Blessing, J., Larano, A., Borisov, V., & Stein‐Thoeringer, C. K. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2374596 · Cited by 42
Kather, J. N., Charoentong, P., Suarez‐Carmona, M., Herpel, E., Klupp, F., Ulrich, A. B., Schneider, M., Zoernig, I., Luedde, T., Jaeger, D., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1126 · Cited by 43
Vivarelli, S., Candido, S., Caruso, G., Falzone, L., & Libra, M. (2020) · Cancers · doi:10.3390/cancers12123636 · Cited by 46
“Vlachogiannis 2018 Stomach, Intestine M A 55 compound-library (FDA approved) Y Y na Patient predictive screening [88]”
BackgroundOkamoto, T., duVerle, D. A., Yaginuma, K., Natsume, Y., Yamanaka, H., Kusama, D., Fukuda, M., Yamamoto, M., Perraudeau, F., Srivastava, U., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.02.012 · Cited by 44
“Patient-derived organoids (PDOs) recapitulate many aspects of the clinical features of original tumors, including genetic alterations and the gene expression profile (Boj et al., 2015; Engel et al., 2020; Fujii et al., 2016; Huang et al., 2015; Karthaus et al., 2014; Nanki et al., 2018; Ooft et al., 2019; Sachs et al.…”
BackgroundPatient-Derived Cancer Organoids for Precision Oncology Treatment
Pernik, M. N., Bird, C. E., Traylor, J. I., Shi, D. D., Richardson, T. E., McBrayer, S. K., & Abdullah, K. G. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11050423 · Cited by 48
“Vlachogiannis et al. (2018) [79] Liver cancer Human primaryliver cancer cells BME + culture with media containing 3 nM dexamethasone Hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular carcinoma/cholangiocarcinoma organoid model creation Organoids formed pseudo-glandular…”
BackgroundLung cancer organoids, a promising model still with long way to go
Ma, H., Zhu, Y.-J., Zhou, R., Yu, Y., Xiao, Z., & Zhang, H.-B. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103610 · Cited by 45
Recent advances in organotypic tissue slice cultures for anticancer drug development
He, L., & Deng, C. (2022) · International Journal of Biological Sciences · doi:10.7150/ijbs.78997 · Cited by 44
“In addition, patient-derived organoids have demonstrated high predictive performance to predict the clinical responses of anticancer drugs in diverse carcinomas [17-20].”
BackgroundTan, K. F., In, L. L. A., & Kumar, P. V. (2023) · ACS Applied Bio Materials · doi:10.1021/acsabm.3c00202 · Cited by 49
Organoids: opportunities and challenges of cancer therapy
Jiang, X., Oyang, L., Qiu, P., Liu, Q., Xu, X., Wu, N., Tan, S., Yang, W., Han, Y., Lin, J., et al. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1232528 · Cited by 47
“The specific cytokine requirements vary among different tumor types, including but not limited to gastric cancer (Vlachogiannis et al., 2018), colorectal cancer (van de Wetering et al., 2015), liver cancer (Broutier et al., 2017), pancreatic cancer (Seino et al., 2018), breast cancer (Sachs et al.,…”
BackgroundRecent Advances in Gut‐ and Gut–Organ‐Axis‐on‐a‐Chip Models
Kim, R., & Sung, J. H. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202302777 · Cited by 53
Hedayat, S., Cascione, L., Cunningham, D., Schirripa, M., Lampis, A., Hahne, J. C., Tunariu, N., Hong, S. P., Marchetti, S., Khan, K. H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2748 · Cited by 46
Self-citationAdaptive Fibrogenic Reprogramming of Osteosarcoma Stem Cells Promotes Metastatic Growth
Zhang, W., Zhao, J.-M., Lin, J., Hu, C.-Z., Zhang, J., YANG, W.-L., Zhang, J., Zhang, J., & Zhu, J. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.06.103 · Cited by 44
Breast cancer organoids from a patient with giant papillary carcinoma as a high-fidelity model
Li, X., Pan, B., Song, X., Li, N., Zhao, D., Li, M., & Zhao, Z. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01171-5 · Cited by 43
Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and Evolving Views
Kim, M. J., Huang, Y., & Park, J. (2020) · Cancers · doi:10.3390/cancers12123638 · Cited by 43
Patient-derived non-small cell lung cancer xenograft mirrors complex tumor heterogeneity
Chen, X., Shen, C., Wei, Z., Zhang, R., Wang, Y., Jiang, L., Chen, K., Qiu, S., Zhang, Y., Zhang, T., et al. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0012 · Cited by 39
RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways
Gudiño, V., Pohl, S., Billard, C. V., Cammareri, P., Bolado‐Carrancio, A., Aitken, S., Stevenson, D., Hall, A. E., Agostino, M., Cassidy, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22531-3 · Cited by 42
Self-citationOn-Chip Replication of Extremely Early-Stage Tumor Behavior
Li, C., Li, S., Du, K., Li, P., Qiu, B., & Ding, W. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c03740 · Cited by 40
Engineered in vitro tumor models for cell-based immunotherapy
Ando, Y., Mariano, C. F., & Shen, K. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.03.076 · Cited by 39
Patient-derived Tumour Organoids: A Bridge between Cancer Biology and Personalised Therapy
Wu, W., Li, X., & Yu, S. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.04.050 · Cited by 42
Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic
Long, Y., Xie, B., Shen, H. C., & Wen, D. (2022) · Cells · doi:10.3390/cells11233868 · Cited by 47
Clinical trials in-a-dish for cardiovascular medicine
Wu, X., Swanson, K., Yıldırım, Z., Liu, W., Liao, R., & Wu, J. C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae519 · Cited by 47
Patient-derived xenograft models: Current status, challenges, and innovations in cancer research
Liu, M., & Yang, X. (2025) · Genes & Diseases · doi:10.1016/j.gendis.2025.101520 · Cited by 61
“105,106 PDX-derived organoids are an innovative model.”
Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review
Tao, W., Sun, Q., Xu, B., & Wang, R. (2025) · Life · doi:10.3390/life15020283 · Cited by 50
“The use of these models in clinical trials, as seen in studies involving ovarian and pancreatic cancers, allows for the creation of more relevant and personalized treatment protocols [64–67].”
Importance of Organoids for Personalized Medicine
Perkhofer, L., Frappart, P., Müller, M., & Kleger, A. (2018) · Personalized Medicine · doi:10.2217/pme-2018-0071 · Cited by 44
Prenylated Indole Diterpene Alkaloids from a Mine-Soil-Derived Tolypocladium sp.
Xu, L., Hai, P., Zhang, S., Xiao, J., Gao, Y., Ma, B., Fu, H., Chen, Y., & Yang, X. (2019) · Journal of Natural Products · doi:10.1021/acs.jnatprod.8b00589 · Cited by 38
Lee, T. W., Lai, A., Harms, J. K., Singleton, D. C., Dickson, B. D., Macann, A., Hay, M. P., & Jamieson, S. M. F. (2020) · Cancers · doi:10.3390/cancers12123743 · Cited by 40
Brok, J. S., Mavinkurve‐Groothuis, A. M. C., Drost, J., Perotti, D., Geller, J. I., Walz, A. L., Geoerger, B., Pasqualini, C., Verschuur, A. C., Polanco, A., et al. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.012 · Cited by 35
Patient-Derived Organoid Models of Human Neuroendocrine Carcinoma
Dijkstra, K. K., van den Berg, J. G., Weeber, F., van de Haar, J., Velds, A., Kaing, S., Peters, D. D. G. C., Eskens, F. A. L. M., de Groot, D.-J. A., Tesselaar, M. E. T., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.627819 · Cited by 38
Hong, H. K., Yun, N. H., Jeong, Y., Park, J., Doh, J., Lee, W. Y., & Cho, Y. B. (2021) · Cancer Medicine · doi:10.1002/cam4.4114 · Cited by 38
Ma, P., Chen, Y., Lai, X., Zheng, J., Ye, E., Loh, X. J., Zhao, Y., Parikh, B. H., Su, X., You, M., et al. (2021) · Macromolecular Bioscience · doi:10.1002/mabi.202100191 · Cited by 40
Stockslager, M. A., Malinowski, S. W., Touat, M., Yoon, J. C., Geduldig, J. E., Mirza, M., Kim, A. S., Wen, P. Y., Chow, K.-H., Ligon, K. L., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109788 · Cited by 39
“…mass assay, we also measured TMZ response using the Cell Titer-Glo (CTG) assay, which measures ATP levels as a proxy for numbers of viable cells, because of the assay’s frequent use in ex vivo drug susceptibility testing (Kulesz-Martin et al., 2013; Tiriac et al., 2018; Vlachogiannis et al., 2018).”
BackgroundMethodInfluentialZhu, L., Retana, D., García‐Gómez, P., Álvaro‐Espinosa, L., Priego, N., Masmudi‐Martín, M., Yebra, N., Miarka, L., Hernández-Encinas, E., Blanco‐Aparicio, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114552 · Cited by 43
“…organoids (PDO) and patient-derived primary cultures (PDC) to test candidate drugs prior to the treatment of the patient, therefore helping to select empirical therapies for the study (Garralda et al, 2014; Gao et al, 2015; Lee et al, 2018; Vlachogiannis et al, 2018; Jiang et al, 2020).”
BackgroundLiver organoids: established tools for disease modeling and drug development
Sun, X.-C., Kong, D.-F., Zhao, J., Faber, K. N., Xia, Q., & He, K. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000105 · Cited by 37
Functional Drug Screening in the Era of Precision Medicine
Napoli, G. C., Figg, W. D., & Chau, C. H. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.912641 · Cited by 45
“A co-clinical trial including rectal cancer organoids demonstrated that PDOs faithfully model the pathophysiology and genetic evolution of their corresponding tumors, and observed highly matched responses with patients to chemoradiation (29).”
BackgroundAtypical teratoid/rhabdoid tumoroids reveal subgroup-specific drug vulnerabilities
Paassen, I., Williams, J. S., Arceo, C. R., Ringnalda, F. C. A. S., Mercer, K., Buhl, J. L., Moreno, N., Federico, A., Franke, N. E., Kranendonk, M. E. G., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02681-y · Cited by 46
Systematic review: predictive value of organoids in colorectal cancer
Sakshaug, B. C., Folkesson, E., Haukaas, T. H., Visnes, T., & Flobak, Å. (2023) · Scientific Reports · doi:10.1038/s41598-023-45297-8 · Cited by 43
“This is also true for the studies included in our meta-analysis, with the exception of the Vlachiogannis et al. 25 study, which utilised a broad panel of both chemotherapies and targeted inhibitors.”
InfluentialAlieva, M., Román, M. B., de Blank, S., Petcu, D., Zeeman, A. L., Dautzenberg, N. M. M., Cornel, A. M., van de Ven, C., Pieters, R., den Boer, M. L., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-00972-6 · Cited by 47
de Oliveira, E. A., Milite, S., Fernández-Mateos, J., Cresswell, G. D., Romero, E. Y., Vlachogiannis, G., Chen, B., James, C. T., Patruno, L., Ascolani, G., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0999 · Cited by 51
Self-citationVicent, S., Lieshout, R., Saborowski, A. L., Verstegen, M. M. A., Raggi, C., Recalcati, S., Invernizzi, P., van der Laan, L. J. W., Alvaro, D., Calvisi, D. F., et al. (2019) · Liver International · doi:10.1111/liv.14094 · Cited by 41
A synopsis of prostate organoid methodologies, applications, and limitations
Gleave, A., Ci, X., Lin, D., & Wang, Y. Z. (2020) · The Prostate · doi:10.1002/pros.23966 · Cited by 41
Precision-based modeling approaches for necrotizing enterocolitis
Kovler, M. L., Sodhi, C. P., & Hackam, D. J. (2020) · Disease Models & Mechanisms · doi:10.1242/dmm.044388 · Cited by 36
Dhara, S., Chhangawala, S., Chintalapudi, H., Aşkan, G., Aveson, V. G., Massa, A. L., Zhang, L., Torres, D., Makohon-Moore, A. P., Lecomte, N., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23237-2 · Cited by 39
A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer
Lier, S., Sellmer, A., Orben, F., Heinzlmeir, S., Krauß, L., Schneeweis, C., Hassan, Z., Schneider, C., Patricia Gloria Schäfer, A., Pongratz, H., et al. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105505 · Cited by 37
Hall, A. E., Pohl, S., Cammareri, P., Aitken, S., Younger, N. T., Raponi, M., Billard, C. V., Bolado‐Carrancio, A., Akan, A. B., Freile, P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30489-z · Cited by 45
The Efficacy of Using Patient-Derived Organoids to Predict Treatment Response in Colorectal Cancer
Su, C., Olsen, K. A., Bond, C., & Whitehall, V. (2023) · Cancers · doi:10.3390/cancers15030805 · Cited by 39
“would suggest susceptibility to anti-EGFR therapy [27].”
BackgroundResultInfluentialTargeting cancer drug resistance utilizing organoid technology
Chai, C., Ji, P., Xu, H., Tang, H., Wang, Z., Zhang, H., & Zhou, W. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114098 · Cited by 38
Signaling pathways in colorectal cancer: implications for the target therapies
Song, Y., Chen, M., Wei, Y., Ma, X., & Shi, H. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00178-y · Cited by 46
“Colonic organoid reveals epigenetic vulnerabilities and is a good model for drug validation at the level of individual patient [251, 252], also, organoids provide an affordable tool for the validation and prediction of targeted therapies [253].”
MethodOrganoids Provide an Important Window on Inflammation in Cancer
Baker, K. (2018) · Cancers · doi:10.3390/cancers10050151 · Cited by 41
“Living organoid biobanks of many types of cancers have now been established and many studies have documented how reliably organoids recapitulate the biology of the original tumors [24,107].”
BackgroundDzobo, K., Rowe, A., Senthebane, D. A., AlMazyadi, M., Patten, V. A., & Parker, M. I. (2018) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2018.0172 · Cited by 38
“The results show that the prediction that a drug will work was around 88% while the prediction that a drug does not work was 100% (Vlachogiannis et al., 2018).”
InfluentialOrganoids: Past Learning and Future Directions
O’Connell, L., & Winter, D. C. (2019) · Stem Cells and Development · doi:10.1089/scd.2019.0227 · Cited by 41
“%) predictive value of patient-derived orga-noids response to chemotherapeutic agents respective to in vivo efficacy [52].”
Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids
Wang, Z., Guo, Y., Jin, Y., Zhang, X., Geng, H., Xie, G., Ye, D., Yu, Y., Liu, D., Zhou, D., et al. (2021) · Cancer Cell International · doi:10.1186/s12935-021-02219-w · Cited by 39
Cho, E. J., Kim, M., Jo, D., Kim, J., Oh, J., Chung, H. C., Lee, S.-H., Kim, D., Chun, S., Kim, J., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02034-1 · Cited by 42
Patient-derived cancer models: Valuable platforms for anticancer drug testing
Genta, S., Coburn, B. A., Cescon, D. W., & Spreafico, A. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.976065 · Cited by 40
Al‐Hamaly, M. A., Turner, L. T., Rivera-Martinez, A., Rodriguez, A., & Blackburn, J. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032288 · Cited by 44
A living ex vivo platform for functional, personalized brain cancer diagnosis
Mann, B., Zhang, X., Bell, N., Adefolaju, A., Thang, M., Dasari, R., Kanchi, K., Valdivia, A., Yang, Y., Buckley, A. A., et al. (2023) · Cell Reports Medicine · doi:10.1016/j.xcrm.2023.101042 · Cited by 40
Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients
Choi, W., Kim, Y., Woo, S. M., Yu, Y., Lee, M. R., Lee, W. J., Chun, J. W., Sim, S. H., Chae, H., Shim, H., et al. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2022.1630 · Cited by 46
“The patient-derived organoid (PDO) establishment rate highly correlates with the tumor cellularity in the original specimen [13].”
Progress and promise of alternative animal and non-animal methods in biomedical research
Freires, I. A., Colón, D. F., Soares, L. F. F., Costa, I. S., de Araújo, L. P., Breseghello, I., Abdalla, H. B., Lazarini, J. G., Rosalen, P. L., Pigossi, S. C., et al. (2023) · Archives of Toxicology · doi:10.1007/s00204-023-03532-1 · Cited by 41
Cruz‐Acuña, R., Kariuki, S. W., Sugiura, K., Karaiskos, S., Plaster, E. M., Loebel, C., Efe, G., Karakasheva, T. A., Gabre, J. T., Hu, J., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci168146 · Cited by 39
Patient-derived tumour models for personalized therapeutics in urological cancers
van de Merbel, A. F., van der Horst, G., & van der Pluijm, G. (2020) · Nature Reviews Urology · doi:10.1038/s41585-020-00389-2 · Cited by 36
Gastman, B., Agarwal, P. K., Berger, A., Boland, G. M., Broderick, S., Butterfield, L. H., Byrd, D. R., Fecci, P. E., Ferris, R. L., Fong, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001583 · Cited by 40
Campioni, G., Pasquale, V., Busti, S., Ducci, G., Sacco, E., & Vanoni, M. (2022) · Cells · doi:10.3390/cells11050866 · Cited by 39
Advanced nanomedicines for the regulation of cancer metabolism
Yang, J., Zhao, Y., Zhou, Y., Wei, X., Wang, H., Si, N., Yang, J. H., Zhao, Q., Bian, B., & Zhao, H. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121565 · Cited by 38
Lung Organoids—The Ultimate Tool to Dissect Pulmonary Diseases?
Bosáková, V., Zuani, M. D., Sládková, L., Garlíková, Z., Jose, S. S., Zelante, T., Kohoutková, M. H., & Frič, J. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.899368 · Cited by 39
High-grade serous ovarian carcinoma organoids as models of chromosomal instability
Vias, M., Gavarró, L. M., Sauer, C. M., Sanders, D. A., Piskorz, A., Couturier, D., Ballereau, S. J., Hernando, B., Schneider, M. P., Hall, J. A. M., et al. (2023) · eLife · doi:10.7554/elife.83867 · Cited by 40
“Patientderived organoids (PDOs) offer improved preclinical cancer models and generally are molecularly representative of the donor, have good clinical annotation, and can represent tumoral intraheterogeneity (Vlachogiannis et al., 2018; Li et al., 2018; Lee et al., 2018; Kopper et al., 2019).”
BackgroundUptake of Functional Ultrasmall Gold Nanoparticles in 3D Gut Cell Models
Sokolova, V., Ebel, J., Kollenda, S., Klein, K., Kruse, B., Veltkamp, C., Lange, C. M., Westendorf, A. M., & Epple, M. (2022) · Small · doi:10.1002/smll.202201167 · Cited by 43
Kang, Y., Deng, J., Ling, J., Li, X., Chiang, Y., Koay, E. J., Wang, H., Burks, J. K., Chiao, P. J., Hurd, M. W., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci151604 · Cited by 36
PhaseFIT: live-organoid phase-fluorescent image transformation via generative AI
Zhao, J., Wang, X., Zhu, J., Chukwudi, C. C., Finebaum, A., Zhang, J., Yang, S., He, S., & Saeidi, N. (2023) · Light Science & Applications · doi:10.1038/s41377-023-01296-y · Cited by 34
“Moreover, gut organoids have been used to model speci fi c gastrointestinal diseases, such as colorectal carcinoma (CRC) 8,9 and in fl ammatory bowel diseases (IBD) 10 .”
MethodZebrafish Avatar-test forecasts clinical response to chemotherapy in patients with colorectal cancer
Costa, B. F., Estrada, M. F., Gomes, A. P., Fernandez, L. M., Azevedo, J., Póvoa, V., Fontes, M., Alves, A., Galzerano, A., Castillo-Martín, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49051-0 · Cited by 43
Three-dimensional tumor cell cultures employed in virotherapy research
Kloker, L. D., Yurttas, C., & Lauer, U. M. (2018) · Oncolytic Virotherapy · doi:10.2147/ov.s165479 · Cited by 37
“86 This work was applied to targeted therapy, but the results might also be valid for virotherapy.”
Cancer Treatment in the Genomic Era
Doherty, G. J., Petruzzelli, M., Beddowes, E. J., Ahmad, S. S., Caldas, C., & Gilbertson, R. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-062917-011840 · Cited by 39
Linden, C. V., & Corbet, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.05.016 · Cited by 34
Targeting Protein Synthesis in Colorectal Cancer
Schmidt, S., Denk, S., & Wiegering, A. (2020) · Cancers · doi:10.3390/cancers12051298 · Cited by 38
Wensink, G. E., Bond, M. J. G., Küçükköse, E., May, A. M., Vink, G. R., Koopman, M., Kranenburg, O., & Roodhart, J. M. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102174 · Cited by 37
Potenza, A., Balestrieri, C., Spiga, M., Albarello, L., Pedica, F., Manfredi, F., Cianciotti, B. C., de Lalla, C., Botrugno, O. A., Faccani, C., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-328042 · Cited by 39
Organoid-on-a-chip: Current challenges, trends, and future scope toward medicine
Li, Z., Li, Q., Zhou, C., Lu, K., Liu, Y., Xuan, L., & Wang, X. (2023) · Biomicrofluidics · doi:10.1063/5.0171350 · Cited by 36
Gao, J., Lan, J., Liao, H., Yang, F., Qiu, P., Jin, F., Wang, S., Shen, L., Chao, T., Zhang, C., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-11434-9 · Cited by 40
“The drug sensitivity of organoids correlated well with clinical treatment response, and the transformation of PDXs from sensitive to resistant to paclitaxel was sequentially generated before and after treatment [29].”
BackgroundInfluentialDerouane, F., Desgres, M., Moroni, C., Ambroise, J., Berlière, M., Bockstal, M. V., Galant, C., van Marcke, C., Vara-Messler, M., Hutten, S. J., et al. (2024) · Breast Cancer Research · doi:10.1186/s13058-024-01788-8 · Cited by 35
“* p < 0.05; *** p < 0.001 models since they recapitulate the genetic and histological features of their parental tumors and help predict response to therapy [44–47].”
BackgroundInfluentialZhang, F., Sahu, V., Peng, K., Wang, Y., Li, T., Bala, P., Aitymbayev, D., Sahgal, P., Schaefer, A., Der, C. J., et al. (2024) · Gut · doi:10.1136/gutjnl-2023-329686 · Cited by 37
Tumour organoids and assembloids: Patient‐derived cancer avatars for immunotherapy
Mei, J., Liu, X., Tian, H., Chen, Y., Cao, Y., Zeng, J., Liu, Y., Chen, Y., Gao, Y., Yin, J., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1656 · Cited by 44
“81 A study using a heterogeneous colorectal cancer PDTO biobank and high-content imaging technology successfully discovered MCLA-158, a bispecific antibody exhibiting therapeutic properties that specifically trigger epidermal growth factor receptor degradation in cancer stem cells.”
BackgroundKarolak, A. M., Poonja, S., & Rejniak, K. A. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007214 · Cited by 35
Driehuis, E., Oosterom, N., Heil, S. G., Muller, I. B., Lin, M., Kolders, S., Jansen, G., de Jonge, R., Pieters, R., Clevers, H. C., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231588 · Cited by 39
Organoids in Translational Oncology
Tatullo, M., Marrelli, B., Benincasa, C., Aiello, E., Im, M., Zavan, B., Ballini, A., Vito, D. D., & Spagnuolo, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092774 · Cited by 38
“…onset of HNSCC by suppression of IL-6 Karakasheva et al. (2018) Metastatic cells of metastatic colorectal and gastro-esophageal carcinoma Colorectal and gastro-esophageal carcinoma Chemotherapy 3D tumoroids were used to test sensitivityand specificity to different drugs Vlachogiannis et al. (2018)”
BackgroundMethodInfluentialThree-Dimensional Culture Systems in Gastric Cancer Research
Alzeeb, G., Metges, J., Corcos, L., & Jossic-Corcos, C. L. (2020) · Cancers · doi:10.3390/cancers12102800 · Cited by 41
Organoids of the Female Reproductive Tract: Innovative Tools to Study Desired to Unwelcome Processes
Heremans, R., Jan, Ž., Timmerman, D., & Vankelecom, H. E. J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.661472 · Cited by 41
“Rightfully wielding this momentum by means of parallel clinical trials (Vlachogiannis et al., 2018; Ooft et al., 2019) will now be of paramount importance to further close the gap between bench and bedside.”
BackgroundEmerging liver organoid platforms and technologies
Lam, D. T. U. H., Dan, Y. Y., Chan, Y.-S., & Ng, H.-H. (2021) · Cell Regeneration · doi:10.1186/s13619-021-00089-1 · Cited by 32
Translational models of 3-D organoids and cancer stem cells in gastric cancer research
Wuputra, K., Ku, C., Kato, K., Wu, D., Saito, S., & Yokoyama, K. K. (2021) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02521-4 · Cited by 34
“Various protocols using different enzymatic digestions have been used, such as dispase II and collagenase XI [50], EDTA and TrypLE [48], Liberase TH and TrypLE Express [49], collagenase and hyaluronidase [50], or Partec CellTrics (Sysmex, Hyogo, Japan; [51]).”
BackgroundMethodInfluentialPersonalized Immunotherapy in Colorectal Cancers: Where Do We Stand?
Hu, L., Lan, H., Huang, D., Li, X., & Jin, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769305 · Cited by 37
Patient‐Derived Upper Tract Urothelial Carcinoma Organoids as a Platform for Drug Screening
Li, Z., Xu, H., Gong, Y., Chen, W., Zhan, Y., Yu, L., Sun, Y., Li, A., He, S., Guan, B., et al. (2021) · Advanced Science · doi:10.1002/advs.202103999 · Cited by 36
Geevimaan, K., Guo, J.-Y., Shen, C., Jiang, J., Fann, C. S. J., Hwang, M., Shui, J., Lin, H.-T., Wang, M.-J. S., Shih, H.-C., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.883437 · Cited by 34
Liver organoids: an in vitro 3D model for liver cancer study
Dong, R., Zhang, B., & Zhang, X. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00890-8 · Cited by 34
“stated that no inverse correlation was observed between the PDO establishment rate and the presence of necrosis based on research of PDOs established from metastatic gastrointestinal cancers [38].”
Background
Metadata
- Authors
- Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernández-Mateos, J., Khan, K., Lampis, A., Eason, K., Huntingford, I., Burke, R., Rata, M., Koh, D.-M., Tunariu, N., Collins, D., Hulkki-Wilson, S., Ragulan, C., Spiteri, I., Moorcraft, S. Y., Chau, I., Rao, S., Watkins, D., Fotiadis, N., Bali, M., Darvish-Damavandi, M., Lote, H., Eltahir, Z., Smyth, E. C., Begum, R., Clarke, P. A., Hahne, J. C., Dowsett, M., de Bono, J., Workman, P., Sadanandam, A., Fassan, M., Sansom, O. J., Eccles, S., Starling, N., Braconi, C., Sottoriva, A., Robinson, S. P., Cunningham, D., & Valeri, N.
- Affiliations
- Institute of Cancer Research (GB)
- Royal Marsden NHS Foundation Trust (GB)
- Division of Molecular Pathology, The Institute of Cancer Research, London, UK.
- Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, UK.
- Division of Clinical Studies, The Institute of Cancer Research, London, UK.
- University of Padua (IT)
- Cancer Research UK Scotland Institute (GB)
- Corresponding author
- Valeri, Nicola
- ORCID
- Vlachogiannis, Georgios
- Hedayat, Somaieh
- Jamin, Yann
- Fernández-Mateos, Javier
- Khan, Khurum
- Lampis, Andrea
- Eason, Katherine
- Huntingford, Ian
- Burke, Rosemary
- Rata, Mihaela
- Koh, Dow-Mu
- Tunariu, Nina
- Collins, David
- Ragulan, Chanthirika
- Spiteri, Inmaculada
- Moorcraft, Sing Yu
- Chau, Ian
- Rao, Sheela
- Watkins, David
- Fotiadis, Nicos
- Bali, Maria
- Darvish-Damavandi, Mahnaz
- Lote, Hazel
- Eltahir, Zakaria
- Smyth, Elizabeth C.
- Begum, Ruwaida
- Clarke, Paul A.
- Hahne, Jens C.
- Workman, Paul
- Sadanandam, Anguraj
- Fassan, Matteo
- Sansom, Owen J.
- Starling, Naureen
- Braconi, Chiara
- Sottoriva, Andrea
- Robinson, Simon P.
- Cunningham, David
- Valeri, Nicola
- Venue
- Science
- Published
- 2018-02-23
- Volume
- 359
- Issue
- 6378
- Pages
- 920-926
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6112415
- OpenAlex
- W2788735115
- Cited by
- 2,096
- References
- 36
- Citations by year
- 2026: 318 · 2025: 286 · 2024: 282 · 2023: 234 · 2022: 262 · 2021: 294 · 2020: 207 · 2019: 124 · 2018: 87
- FWCI
- 66.95
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- FP7 People: Marie-Curie Actions (CIG334261)
- National Institute for Health Research (A62)
- Cancer Research UK (CEA A18052)
- European Commission (Marie Curie CIG 618154)
- European Research Council (331301)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Physical Sciences › Engineering › Biomedical Engineering › 3D Printing in Biomedical Research
- Keywords
- patient-derived organoids, metastatic gastrointestinal cancer, colorectal cancer, gastroesophageal cancer, treatment response prediction, drug screening, tumor organoids, orthotopic xenograft, personalized medicine, biobanks, molecular profiling, anticancer agents
- MeSH terms
- Animals, Antineoplastic Agents, Gastrointestinal Neoplasms, Humans, Neoplasm Metastasis, Organoids, Phenylurea Compounds, Pyridines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Genomics, Mice, Precision Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.